Every 424B that Coeptis Therapeutics Holdings Inc. (COEP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow COEP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COEP filings page.
Coeptis Therapeutics Holdings, Inc. files Supplement No. 2 to its S-4 prospectus to incorporate its Annual Report on Form 10-K for the year ended December 31, 2025. The 10-K discloses a net loss of $12,277,192 for 2025 and an accumulated deficit of $109,953,728. The filing states shares outstanding were 6,223,221 as of March 18, 2026 and reports an aggregate market value held by non-affiliates of $28,225,766 based on a $7.80 closing price.
The 10-K details biotech and technology divisions, material collaborations and licenses (including Deverra, Vy-Gen and the University of Pittsburgh), a going-concern explanatory paragraph, financing needs, and a pending merger/spin-out transaction expected to close in Q2 2026. Risk factors include substantial doubt about going concern, the cost and uncertainty of clinical development, reliance on partners, and the need for additional capital.
Coeptis Therapeutics Holdings, Inc. registers an offering of 107,500 shares of common stock, pre-funded warrants to purchase 67,500 shares, Series A warrants to purchase 153,125 shares and Series B warrants to purchase 153,125 shares.
This prospectus supplement, dated March 23, 2026, supplements the June 14, 2023 prospectus and attaches the company’s Form 10-K for the year ended December 31, 2025. The supplement states none of the Series A or Series B warrants have been exercised and notes a 20-for-1 reverse stock split effected December 30, 2024. The Form 10-K discloses a going concern paragraph, net loss of $12,277,192 for 2025, accumulated deficit of $109,953,728, shares outstanding of 6,223,221 as of March 18, 2026, and market close price of $11.07 on March 19, 2026.
Coeptis Therapeutics Holdings, Inc. registers the resale of up to 3,919,349 shares of Common Stock by selling stockholders via a prospectus supplement dated March 23, 2026. The amount includes 100,000 shares held by certain selling stockholders, up to 3,737,472 shares issuable to YA II PN, LTD. (“Yorkville”) under a Standby Equity Purchase Agreement, and 81,877 shares issued in partial conversion of a convertible note.
The supplement attaches the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and updates the base prospectus. Shares are being offered for resale by named selling stockholders rather than as a primary offering by the issuer. Shares outstanding were 6,223,221 as of March 18, 2026, and the Nasdaq closing price was $11.07 as of March 19, 2026.
Coeptis Therapeutics Holdings, Inc. is registering the resale of up to 604,000 shares of its common stock on a resale basis to satisfy registration rights granted to certain selling stockholders, as set forth in a Prospectus Supplement dated March 23, 2026.
The 604,000 shares consist of issued shares and shares issuable upon exercise of various warrants and pre-funded warrants. Shares outstanding were 6,223,221 shares as of March 18, 2026. The company’s common stock traded at $11.07 on March 19, 2026 on the Nasdaq Capital Market under the symbol COEP.
Coeptis Therapeutics Holdings, Inc. has issued a prospectus supplement to correct the “Principal Stockholders of Proposed Combined Company” table in its S-4 proxy statement/prospectus for the planned merger.
The supplement assumes that the merger consideration will equal approximately 79% of the combined company’s issued and outstanding common stock at closing, based on 5,762,221 Coeptis shares outstanding on the date of the supplement. Under these assumptions, BSG Series LLC is shown as beneficially owning 22,459,490 shares, or 73.37%, immediately after the merger, with executive officers and directors as a group at 854,775 shares, or 2.79%. BSG Series LLC is expected to distribute its merger shares pro rata to its members in a “BSG Dividend,” after which no single BSG member will beneficially own more than 5% of Coeptis common stock.
Coeptis Therapeutics Holdings, Inc. filed a prospectus supplement covering the resale, from time to time, by selling stockholders of up to 3,919,349 shares of common stock. This total includes 100,000 shares held by selling stockholders, up to 3,737,472 shares tied to the Yorkville SEPA (including 20,000 commitment shares and up to 3,717,472 issuable), and 81,877 shares issued upon partial note conversion.
The supplement attaches the company’s Q3 2025 report. For the quarter ended September 30, 2025, sales were $237,441 with a net loss of $2,898,763; year-to-date net loss was $10,654,290. Cash was $4,908,487 as of September 30, 2025. Financing activities provided $11,290,728 year-to-date, including 165,000 SEPA shares for $2,039,195 and a private placement of 436,467 shares for $5,000,000. The company disclosed that these conditions raise substantial doubt about its ability to continue as a going concern. Shares outstanding were 5,340,111 as of November 11, 2025; this is a baseline figure, not the amount being offered.
Coeptis Therapeutics Holdings, Inc. filed Prospectus Supplement No. 9 to its November 29, 2023 prospectus, covering the resale of up to 12,080,000 shares of common stock by selling stockholders. The supplement also attaches the company’s Form 10‑Q for the quarter ended September 30, 2025.
The registered resale shares consist of:
- 6,527,000 currently issued shares
- 1,223,000 shares issuable upon exercise of pre‑funded warrants
- 2,000,000 shares issuable upon exercise of Series A Warrants
- 2,000,000 shares issuable upon exercise of Series B Warrants
- 210,000 shares issuable upon exercise of underwriter warrants from the June 2023 offering
- 120,000 shares issuable upon exercise of placement agent warrants from the October 2023 private placement
The company states the registration is to satisfy registration rights granted to selling stockholders. As context, shares outstanding were 5,340,111 as of November 11, 2025. The common stock trades on Nasdaq under “COEP,” and the reported closing price was $14.15 on November 13, 2025.